Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Pegcetacoplan in Cold Agglutinin Disease
2021-003160-27Phase 3Terminated
- Sponsor
- Sobi
- Start
- Feb 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cold agglutinin disease (CAD) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Response to treatment at Week 24. Started Feb 2022; status: terminated.
02
Drugs
pegcetacoplan
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on 2021-003160-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003160-27.